Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis

Fig. 2

Proportion of patients with low disease activity and clinical remission at 12 months. a Proportion of subjects with low disease activity and clinical remission at 12 months, per-protocol subset (main analysis). b Proportion of subjects with low disease activity and clinical remission at 12 months, intention-to-treat subset. c Adjusted differences between groups and non-inferiority testing for low disease activity and clinical remission, per-protocol subset (main analysis). d Adjusted differences between groups and non-inferiority testing for low disease activity and clinical remission, intention-to-treat subset. Low disease activity was defined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) < 4 and Physician Global Assessment < 4, Patient Global Assessment < 4 and axial pain at night < 4. Clinical remission was defined by BASDAI ≤ 2, Physician Global Assessment ≤ 2 and Patient Global Assessment ≤ 2

Back to article page